ORPHA:26137
Juvenile temporal arteritis
Also known as: JTA · Non-giant cell granulomatous temporal arteritis with eosinophilia
Publications
56
42.4th percentile
Trials
0
Interventional, condition-specific
Researchers
278
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
A rare vasculitis characterized by mostly unilateral inflammation of the temporal artery affecting patients up to fifty years of age. Patients typically present with a lump in the temporal region or a prominent temporal artery and often have headaches. Males are more frequently affected than females, and major systemic symptoms, ocular complications, and a biological inflammatory syndrome are usually absent, although peripheral blood eosinophilia may be seen. Histopathological analysis shows arteritis predominantly of the intima with possible extension to the perivascular tissue. The presence of granuloma, giant cells or fibrinoid necrosis is rare. Clinical relapses after one episode are uncommon.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016848
- UMLS:C0751547
Additional Mondo synonyms (1)
non-giant cell granulomatous temporal arteritis with eosinophilia
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
56 matched papers (28 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialPartial
None under the specific name; 96 for broader category arteritis
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
56
56 papers have ever been published on this condition (under this name). For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
56 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
28 in the last 10 years · medium confidence · 42.4th percentile (publications denominator)
Phrase hits: 56 · MeSH hits: 0
Who's working on it?
278
Distinct author names in 56 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01
- 02Agard C2 papers · 2019
Department of Internal Medicine, CHU de Nantes, Nantes, France.
Papers in Europe PMC - 03Espitia O2 papers · 2019
Department of Internal Medicine, CHU de Nantes, Nantes, France.
Papers in Europe PMC - 04Kikuchi Y2 papers · 2021
Department of General Internal Medicine, Hiroshima University Hospital, Japan.
Papers in Europe PMC - 05Pistorius MA2 papers · 2019
Department of Internal Medicine, CHU de Nantes, Nantes, France.
Papers in Europe PMC - 06Abubaker M1 paper · 2000Papers in Europe PMC
- 07Adham TM1 paper · 2014
Pediatric Department, Faculty of Medicine, Ain Shams University, Abbassia, Cairo 11566, Egypt.
Papers in Europe PMC - 08Adkins G1 paper · 2005Papers in Europe PMC
- 09Agudelo CA1 paper · 2000Papers in Europe PMC
- 10Akalin T1 paper · 2014
Kayseri Education and Research Hospital, Department of Internal Medicine, Kayseri, Turkey. tayfunakalin@yahoo.com.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 96 trials are registered for arteritis, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
96 interventional trials matched arteritis, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: arteritis
96
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT06957002·NOT YET RECRUITING·Bosentan in the Treatment of Giant Cell Arteritis
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT07325357·NOT YET RECRUITING·Effect of Pirfenidone on TA Fibrosis
Conditions: Takayasu Arteritis·Matched via name phrase
- NCT06498089·RECRUITING·A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's Arteritis
Conditions: Takayasu Arteritis·Matched via name phrase
- NCT07060274·RECRUITING·Halo Sign Vanishing Time After Steroids Outbreak in GCA Patients
Conditions: Giant Cell Arteritis (GCA) · Doppler Ultrasound·Matched via name phrase
- NCT06335888·RECRUITING·A Clinical Trial to Investigate 18F-AzaFol in the Diagnosis of Large Vessel Vasculitis
Conditions: Giant Cell Arteritis·Matched via name phrase
- NCT07001059·RECRUITING·oPtic Nerve Sheath Evaluation in gianT Cell aRtheritis by UltraSound
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT04012905·RECRUITING·Giant Cell Arteritis: Comparison Between Two Standardized Corticosteroids Tapering
Conditions: Giant Cell Arteritis·Matched via name phrase
- NCT06178419·RECRUITING·Remote Ischemic Conditioning for Cerebral Ischemia in Patients With Takayasu Arteritis (TARIC-1)
Conditions: Cerebral Ischemia · Takayasu Arteritis·Matched via name phrase
- NCT06833411·NOT YET RECRUITING·Treatment for Giant Cell Arteritis With Tocilizumab and 8 as Compared to 26 Weeks of Prednisone
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT07013838·NOT YET RECRUITING·The Efficacy and Safety of Deucravacitinib in Takayasu's Arteritis
Conditions: Takayasu Arteritis (TAK)·Matched via name phrase
- NCT07720804·NOT YET RECRUITING·Kinetics of C-Reactive Protein in Giant Cell Arteritis Following Glucocorticoid Initiation: A Pilot Study (GIDEON)
Conditions: Giant Cell Arteritis (GCA)·Matched via name phrase
- NCT06763783·ENROLLING BY INVITATION·Vaccination Against Herpes Zoster in Patients With Inflammatory Rheumatic Diseases
Conditions: Systemic Vasculitis · Spondylarthropathies · Psoriatic Arthritis · Scleroderma·Matched via name phrase
- NCT05102448·RECRUITING·Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis
Conditions: Takayasu Arteritis·Matched via name phrase
- NCT07451665·NOT YET RECRUITING·Efficacy and Safety of Vunakizumab and Ivarmacitinib in the Treatment of Active Takayasu's Arteritis
Conditions: Takayasu Arteritis (TAK)·Matched via name phrase
- NCT07087912·RECRUITING·Safety and Immunogenicity of the Live Attenuated Tetravalent Butantan-Dengue Vaccine in Autoimmune Rheumatic Diseases
Conditions: Rheumatoid Arthritis (RA) · Juvenile Idiopathic Arthritis (JIA) · Systemic Lupus Erythematosus (SLE) · Juvenile Systemic Lupus Erythematosus·Matched via name phrase
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Juvenile temporal arteritis" OR "Non-giant cell granulomatous temporal arteritis with eosinophilia"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Juvenile temporal arteritis" OR "Non-giant cell granulomatous temporal arteritis with eosinophilia"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"arteritis"
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: JTA
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-26T23:20:14.318Z
